Astra Zeneca slashes 400 more jobs in Sweden

Another 400 jobs will be cut from Anglo-Swedish pharmaceutical manufacturer Astra Zeneca, the company has announced, with the majority of the redundancies in Södertälje, south of Stockholm.

Astra Zeneca slashes 400 more jobs in Sweden

According to the company this is an implementation of the cuts that the company presented in February, when the company announced that 1,100 employees would have to go.

“We realized already then that it was administrative personnel and related services that would be affected. Those who are affected in this cut are economists, lawyers, the personnel department, IT-technicians, lab technicians and those types of broad competencies,” said Astra Zeneca’s head of information, Ann-Leena Mikiver to news agency TT.

According to national broadcaster Sveriges Television (SVT), the cuts are the result of concluded negotiations between the company leadership and the union.

The 400 jobs are disappearing as a consequence of cuts to the research side of the company. 75 percent of the cuts will take place in the department that handles the upkeep of the labs and machines.

According to Mikiver these may not be the last cuts the company will see in the near future.

“We are a large and global company trying to make our way in a very competitive business. There’s always restructuring going on and that is never finished,” she told TT.

However, the company aims to be supportive of personnel in the case of redundancies. They have planned labour market days where 100 companies have been invited to meet that wish to make new connections.

The company has also hosted ‘start-up’ days, and offer coaching and seminars for those who are choosing to embark on a new course in life.

According to the company, the first scientists have already left the company.

“The first 50 left two weeks ago. Some will leave during the summer and others early this autumn and the whole move should be completed in December,” she told TT.

TT/The Local/rm

Member comments

Log in here to leave a comment.
Become a Member to leave a comment.
For members


IN NUMBERS: How badly did the AstraZeneca suspension hit Germany’s vaccine rollout?

The temporary suspension of AstraZeneca’s Covid-19 vaccine last week threatened to throw another spanner into the machinery of a vaccine programme that has gotten off to a slow start. What do the numbers say?

IN NUMBERS: How badly did the AstraZeneca suspension hit Germany's vaccine rollout?
A Pfizer-BioNTech vaccine is administered at a vaccine site in Bielefeld. Photo: DPA

Here is a look at some of the key data.

Did AstraZeneca suspension hit the pace of the vaccination regime?

The pace of the vaccine programme did indeed slow down slightly in the wake of the AstraZeneca suspension, numbers provided by the Ministry of Health show.

Some 286,000 people received a vaccination on Wednesday of this week, which marked a stagnation in the pace of the rollout. That is a big improvement on the 209,000 who were vaccinated seven days beforehand (Wednesday March 17th). But it is only slightly higher than the 280,000 jabs given on Wednesday March 10th.

That dip coincides with the decision to suspend use of AstraZeneca, which was made on March 15th and was lifted on March 19th.

Health Minister Jens Spahn suspended use of the vaccine after the Paul Ehrlich Institute found a possible link to a highly rare form of cerebral thrombosis that caused the deaths of three women shortly after they had received the jab.

Three days later the European Medicines Agency affirmed that the jab was “safe and effective” but updated its advice on side effects.

The high point of Germany’s vaccine rollout to date came on Friday March 12th, when 304,000 people received a vaccine in a single day. As of Thursday, a total of 3.6 million people in Germany had received both doses of a vaccine, according to the Robert Koch Institute (RKI).

Since mid-February there had been a clear increase in speed in a week-to-week comparison.

While the rate of vaccinations is clearly on the rise again, DPA reports that some federal states still have not reactivated their online booking system for appointments since the AstraZeneca suspension.

As of Wednesday, 15.6 million doses of vaccine had been delivered to Germany: 70 percent has been the BioNTech jab, 23 percent from AstraZeneca and seven percent from the US vaccine Moderna.

Are there millions of unused doses being stockpiled?

Various German media outlets have claimed that the federal states have been hoarding millions of doses without using them.

State premier of Hesse, Volker Bouffier has rejected this claim as “simply wrong.”

A closer look at the numbers shows it is misleading to say that state are stockpiling doses for no good reason, although it is not completely untrue.

The Health Ministry recommends that states keep stockpiles of vaccines in case unexpected delivery delays lead to appointments being cancelled, and to ensure that there are enough doses in stock for people to have second vaccinations. 

For Moderna the ministry recommends keeping 50 percent as backup, for BioNTech, 25 percent.

SEE ALSO: BioNTech starts Covid-19 vaccine production at new German site

Research by der Spiegel shows that the states have been very efficient in their use of BioNTech, but much less so with AstraZeneca.

None of the states have had serious issues with the BioNTech/Pfizer vaccine, which makes up 11 million of the 15.6 million doses that have arrived in Germany so far.

The Moderna vaccine only makes up a relatively small fraction of Germany’s programme (1.1 million doses so far) but is also being used efficiently.

The problems arise with the AstraZeneca vaccine. There have been serious issues with deliveries of this vaccine, with the British-Swedish company under-delivering on purchase agreements for the first quarter.

Still though, some German states have been more effective in using the vaccine than others.

The small city-state of Bremen has done the best job of including the British-Swedish vaccine in its programme, having used 82 percent of its stock.

SEE ALSO: Why have tens of thousands of Germany’s AstraZeneca vaccines not been used?

Rhineland-Palatinate has also done a good job: three-quarters of its stocks have been used.

Right at the back of the field is Saxony, which has used just 28 percent of its AstraZeneca vaccines. According to Spiegel’s research, the vaccine had been set aside for various pilot projects including vaccinations in GPs practices and in hotspot regions.

Due to the slow implementation of these projects, most of the stock is still sitting unused in warehouses.

Pace of vaccinations among over-80s

There are considerable differences between the federal states in their efficiency in vaccinating the oldest members of society.

While data produced by the Robert Koch Institute shows that 73 percent of those over 80 in Saarland have been vaccinated at least once, only around 59 percent of this age group in Baden-Württemberg have had their first jab.

Baden-Württemberg’s social affairs minister, Manne Lucha, recently promised that everyone over the age of 80 would receive a jab by the end of March.

In the northeast, less than half of the over 80s have been vaccinated in Mecklenburg-Western Pomerania. 

Vaccinations over Easter and beyond

Most states have said that they intend to continue vaccinating people through the Easter break.

In the week after Easter, according to a decision of the federal and state governments last week, GPs are also to set to join the vaccination campaign, but initially with just under one million doses per week – about 20 doses for each practice. 

After Easter, the deliveries are to increase significantly. According to the Health Ministry, up to 15.3 million doses of vaccine are to be delivered in April – only 4.5 million less than in the entire first quarter.

READ MORE: What you need to know about Germany’s pledge to make vaccines available at GP practices